Day 1 - Thursday, 26 May 2016
Meeting category
Date(s)
26 May 2016
Program Language
English
Location
Rome,
Italy
Meeting type
Live Meeting
Organizer
International Workshop on Hepatitis C: Resistance and New Compounds 2016
Enduring Materials
Session 1 -
Host-acting broad-spectrum antiviral drugs from nature
Juana Díez, PhD
Universitat Pompeu Fabra, Spain
How do we test for HCV RAV's (technology-based presentation)
Do we need surveillance for DAA resistance: how to implement it'
Stephanie Popping, MD
Erasmus Medical Center, The Netherlands
Session 2 -
What do we know about RAV's today
Abstract presentations
Substantial presence of natural NS3, NS5A and NS5B HCV-resistance in real practice, and their impact on direct-acting antiviral treatment in genotypes 1-4
Dr. V. Cento
-
Characterization of Resistance-Associated Variants at baseline and failure of All-Oral Antiviral Therapy of Hepatitis C
Dr. A. Lai
-
Session 3 -
What do we need to know about RAV's clinically
Stefan Zeuzem, MD
JW Goethe University Hospital, Germany
Abstract presentations
Virological failures to DAA in real life show frequent resistance associated variants and may require re-treatment with unconventional regimens
Dr. V.C. Di Maio
-
Treatment emergent variants to combined direct antiviral agents therapy against hepatitis C virus
Dr. F. Garcia
-
Total HIV DNA increases in lymphomonocytes of HCV/HIV co-infected patients during and after DAA treatment
Dr. I. Abbate
-
Overview
The 11th International Workshop on Hepatitis C: Resistance and New Compounds took place on 26 May 2016 as a half-day program of the European Meeting on HIV & Hepatitis 2016 (Rome, Italy, 25 - 27 May 2016).
The exciting progress in the development of Hepatitis C antivirals provides hope for new treatment strategies to clear this virus from infected individuals. Our understanding of Hepatitis C virus replication, its pathogenesis and resistance is increasing as these new antivirals progress through clinical development to the market, however many questions remain. The objective of this program is to provide an international forum where all questions and recent progress in the development and study of Hepatitis C antivirals can be discussed among researchers from academia and industry with key clinical investigators.
The Organizing Committee
General Information
Meeting Objectives
This meeting aims to:
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies